Facilitated By

San Antonio Medical Foundation

A Phase 2, Multicenter, Open-Label, Multi-Cohort Study To Assess Safety And Efficacy Of CC-90011 In Combination With Nivolumab In Subjects With Advanced Cancers

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
HJF
Research Start Date
Status
Inactive

The primary objective of the study is to evaluate in each individual cohort the overall response rate in subjects with SCLC or sqNSCLC treated with CC-90011 in combination with nivolumab.

Collaborative Project
Clinical Care
Cancer
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.